Search hospitals > Ohio > Cleveland
University Hospitals Cleveland Medical Center
Claim this profileCleveland, Ohio 44106
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lymphoma
Conducts research for Solid Tumors
927 reported clinical trials
125 medical researchers
Summary
University Hospitals Cleveland Medical Center is a medical facility located in Cleveland, Ohio. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Lymphoma, Solid Tumors and other specialties. University Hospitals Cleveland Medical Center is involved with conducting 927 clinical trials across 1,214 conditions. There are 125 research doctors associated with this hospital, such as Pedro M. Barata, Amit Mahipal, MD, Afshin Dowlati, MD, and Lauren Henke, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Lung Cancer
Global LeaderStage IV
Stage III
KRAS positive
Top PIs
Pedro M. BarataTulane University Health Sciences Center1 year of reported clinical research
Studies Parotid Gland Cancer
Studies Kidney Cancer
20 reported clinical trials
52 drugs studied
Amit Mahipal, MDMayo Clinic3 years of reported clinical research
Studies Cancer
Studies Bile Duct Cancer
19 reported clinical trials
36 drugs studied
Afshin Dowlati, MDUniversity Hospitals Cleveland Medical Center1 year of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
19 reported clinical trials
33 drugs studied
Lauren Henke, MDWashington University School of Medicine3 years of reported clinical research
Studies Lung Cancer
Studies Stomach Cancer
17 reported clinical trials
29 drugs studied
Clinical Trials running at University Hospitals Cleveland Medical Center
Crohn's Disease
Multiple Myeloma
Coronavirus
Breast Cancer
Psoriasis
Ovarian Cancer
Small Cell Lung Cancer
Cancer
Chronic Obstructive Pulmonary Disease
Lung Cancer
Vedolizumab
for Ulcerative Colitis and Crohn's Disease
The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Recruiting3 awards Phase 3
Vedolizumab
for Crohn's Disease
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive either a high dose or low dose of vedolizumab once every 8 weeks. They will receive the same dose every time.
Recruiting2 awards Phase 36 criteria
Upadacitinib
for Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy. Upadacitinib (RINVOQ) is a drug approved in adults for moderate- to severely active CD and is being developed for moderate- to severely active CD in pediatric participants. This study is conducted in 2 periods: Period 1 is comprised of two phases: a 12-week open-label induction phase which means that the study doctor and participants know that participants will receive UPA Dose-A (or the adult equivalent based on body weight) followed by a 52-week double-blind maintenance phase meaning that neither the participants nor the study doctors will know which dose of upadacitinib will be given(UPA Dose B or Dose C). Period 2 is a 156-week open-label extension of Period 1. Approximately 110 pediatric participants with moderate to severely active CD will be enrolled at approximately 92 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily at approximately the same time each day, with or without food. Participants will have a safety follow up for 30 days after discontinuation from any time point within the study. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting2 awards Phase 32 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University Hospitals Cleveland Medical Center?
Where is University Hospitals Cleveland Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does University Hospitals Cleveland Medical Center accept?
What awards or recognition has University Hospitals Cleveland Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.